Subodh Samrat

PeerJ Reviewer

Summary

Subodh Kumar Samrat, PhD
University of Arizona
Tucson, AZ USA
[email protected]

EDUCATION
University of Alberta, Edmonton, Canada .......... 2013
Ph.D., Immunology
Thesis: Modulation of immune response by HCV-derived F, Core and NS3 Proteins
Pondicherry Central University, Pondicherry, India.....................................May 2005
Master of Science, Biotechnology
Thesis: Extraction of 2, 4-diacetylphloroglucinol (DAPG) from Banana rhizobacterium and evaluation of DAPG for antifungal activity
CSA University of Agriculture & Technology, Kanpur, India.........……...…...July 2003
Bachelor of Science, Agriculture
Wayne State University.………………………………………………..………. Detroit, MI
Post Doctoral Fellow (Lab of Dr. Haidong Gu, Ph.D.).........................................July 2014-Present
• Identify the differential mechanism used by HSV-I ICP0 to degrade different isoform of PML, key component of ND10 macromolecular structure.
• Identified the mechanism involved in translocation of HSV-I ICP0 from the nucleus to
• Identified the involvement of the late viral protein in HSV-I ICP0 translocation
• Manage several undergraduate students

Biotechnology HIV Immunology Infectious Diseases Microbiology Molecular Biology Virology

Past or current institution affiliations

University of Alberta

Wayne State University

Work details

Postdoctoral research associate I

University of Arizona

November 2020

Pharmacy and Toxicology

Currently, working on screening small molecule inhibitors against SARS-CoV-2 3C pro and papain-like protease. Apart from this, I am working on Dengue viruses and Zika virus which cause significant human diseases. My current project involves screening of a single domain, termed VHH (variable domain of camelid heavy-chain-only antibody (HcAb)) or nanobody (Nb) against DENV and Zika full length E protein and E domain 3 protein. DEN2 and Zika envelope (E) protein is highly conserved and key target for developing therapeutic antibodies and vaccines. Nanobody provide many advantages, including comparable high affinity to targets, high intrinsic stability, high flexibility to reach epitopes normally unreachable by conventional antibodies, ease of production and scale-up, low immunogenicity, good tissue penetration and distribution, ease of cross-linking to form multivalent Nbs, lack of Fc domain to avoid ADE, and less cytotoxicity. These benefits enhance the practical application to the treatment of DENV and Zika virus infections by nanobody and the results from this project will establish a solid basis in general for nanobodies as novel therapeutics. If successful, novel therapy will be developed to combat DENV and Zika infections.

Ph.D

University of Alberta

September 2008 - September 2013

Department of Surgery

Modulation of immune response by HCV-derived F, Core and NS3 Proteins

Post Doc fellow

Wayne State University

July 2014 - August 2018

Biological Sciences

I have done my PhD in Viral Immunology. Specifically, work on immune response generated by HCV-antigen in human and mouse cells. Currently, I am working on HSV-1 virus and dealing with host-pathogen interaction.

Wadsworth Center

Genetics

Post Doctoral Fellow

University of Alberta

October 2013 - June 2014

Department of Surgery

Modulation of immune response by HCV-derived F, Core, and NS3 Proteins